Cameroon: World Hemophilia Day - Population Schooled On Treatment Mechanisms

[Cameroon Tribune] Sensitisation activities to commemorate the day end today in Yaounde.
Source: AllAfrica News: Health and Medicine - Category: African Health Source Type: news

Related Links:

Publication date: November 2020Source: Urology Case Reports, Volume 33Author(s): Karthik Rao, Mohan Keshavamurthy, Shakir Tabrez, Sreeharsha Harinatha, Niti Raizada
Source: Urology Case Reports - Category: Urology & Nephrology Source Type: research
Condition:   Hemophilia A Intervention:   Drug: Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection Sponsors:   Zhengzhou Gensciences Inc;   Haimen Gensciences lnc Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Authors: Khubrani AM, Alshomer FM, Alassiri AH, AlMeshal O Abstract [No Abstract Available]. PMID: 32601647 [PubMed - in process]
Source: Saudi Medical Journal - Category: Middle East Health Tags: Saudi Med J Source Type: research
CONCLUSIONS: According to this model, use of SHL rFVIII versus EHL rFVIII products could lead to savings for the Spanish National Health System. PMID: 32597317 [PubMed - as supplied by publisher]
Source: Expert Review of Pharmacoeconomics and Outcomes Research - Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research
Basel, 29 June 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from its haemophilia A clinical programme will be presented at the International Society on Thrombosis and Haemostasis (ISTH) 2020 Congress on 12-14 July 2020. Data will include updated safety results from the phase IIIb STASEY study of Hemlibra ® (emicizumab) and new results from the phase III HAVEN 5 study of Hemlibra. Data will also include insights into the impact of living with haemophilia A. Spark Therapeutics (a member of the Roche Group) will also present data from the initial dose cohorts of its phase I/II SPK-8011 gene ther...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
Innovations in diagnostic techniques, genomic analysis, stem cell treatments, and gene therapies have the potential to revolutionize our approach to many birth defects and genetic diseases that we are presently able to manage only after birth. In their review of gene and stem cell therapies for fetal care in this issue of JAMA Pediatrics, O ’Connell et al provide a comprehensive perspective on current practice and the probable future for affected pregnancies. Many of the treatments described are presently at the experimental stage. In the theoretical case study of corrected hemophilia before birth, the authors descri...
Source: JAMA Pediatrics - Category: Pediatrics Source Type: research
An amendment to this paper has been published and can be accessed via the original article.
Source: Journal of Cardiothoracic Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Tags: Correction Source Type: research
Acquired Haemophilia A is a rare acquired bleeding disorder caused by autoantibodies directed against Factor VIII, which neutralize FVIII activity. These inhibitors differ from alloantibodies against FVIII which can occur in congenital Haemophilia A after repeated exposures to plasma-derived or recombinant FVIII products. In most cases the disease occurs suddenly in subjects without personal or familiar history of bleedings, with symptoms that may be mild, moderate or severe. However, only laboratory alterations are present in   ̴ 30% of patients. The incidence varies from 1 to 4 cases per million/year; more tha...
Source: Mediterranean Journal of Hematology and Infectious Diseases - Category: Hematology Authors: Source Type: research
Authors: Arain A, Muhsen IN, Abdelrahim M Abstract Acquired haemophilia is a severe haematological disorder characterised by the presence of anti-factor VIII antibodies. Although rare, it can lead to serious bleeding complications. Acquired haemophilia can be seen in patients with malignancies as a paraneoplastic phenomenon. This is a case of a 52-year-old patient who presented with haematuria and retroperitoneal bleeding soon after being diagnosed with pancreatic adenocarcinoma and subsequently was found to have acquired haemophilia. The treatment of underlying malignancy with chemotherapy may accelerate the eradi...
Source: Ecancermedicalscience - Category: Cancer & Oncology Tags: Ecancermedicalscience Source Type: research
Conclusion: Although very rare, AGL should be kept in mind in the differential diagnosis of renal pelvic hemorrhage. In the patient who has an underlying history of coagulopathy nephrectomy can be avoided when there is awareness of AGL.
Source: Medicine - Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research
More News: African Health | Cameroon Health | Haemophilia | Hemophilia